Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
ConditionHepatic Encephalopathy
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age20-65
SponsorTanta University
About this trial
Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Cirrhotic patient with at least one previous episode of hepatic encephalopathy.
Adult Patients aging from 20 to 65 years old
Disqualifiers
Active GIT bleeding.
Major psychiatric illness (psychosis & epilepsy).
Renal insufficiency (S.Cr 2mg/dl).
Trial design
Design model
Parallel
Treatments tested in this trial
Rifaximin
DrugRifaximin 550 mg twice daily for 6 months
Nitazoxanide
DrugNitazoxanide 500 mg twice daily for 6 months
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: RifaximinActive comparator 1 intervention
Group B: NitazoxanideExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of encephalopathy episodes during treatment
The number of encephalopathy episodes during treatment
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov